Legal News In Brief
Mylan files suit against Pittsburgh Post-Gazette: Mylan filed a civil suit against the Pittsburgh Post-Gazette, alleging that the newspaper improperly obtained and misconstrued confidential internal documents in a series of articles about its West Virginia generic plant. "The articles mischaracterized a minor deviation from internal Mylan procedure, creating the false appearance of significant quality and regulatory issues at Mylan's Morgantown, W.Va. plant when no such issues existed," Mylan said. The suit, filed in the Circuit Court of Monongalia County, W.Va., stemmed from an initial story published in late July (1"The Pink Sheet" DAILY, July 30, 2009). In an Aug. 20 Post-Gazette article, Publisher and Editor-in-chief John Robinson Block stated that the allegations are "meritless" and that the paper plans to challenge the suit. An FDA inspection following the first published Post-Gazette piece has been closed, and the agency noted that "the firm appears to have conducted an adequate investigation." The agency said it plans no additional action
You may also be interested in...
FDA’s GMP warning letter to Mylan cites failure to complete a required content uniformity test for generic Imodium manufactured at Puerto Rico plant.
A federal court rules that broad scientific presentations do not constitute prior art in this case, a finding that gives Merck three years to consider an OTC switch.
With new execs in place, firm raises EPS guidance for 2009, just days after coming under fire for quality control allegations.